控制系统优化：团队通过对主手的高精度运动学与动力学建模，实现了操作的轻便与流畅，重点解决了以钢带或钢丝传动的手术器械在运动补偿和间隙控制 方面的核心难题。 系统性能提升：通过多环节协同优化，系统整体延迟控制在80毫秒以内。视频系统实现了40毫秒内完成4K荧光信号的采集与传输，同时通过结构设计与运 动控制算法的联合补偿，有效抑制了机械传动中的间隙与弹性变形。 来源：猎云网 12月31日，杭州康基唯精医疗机器人有限公司（以下简称"唯精医疗"）宣布，已完成亿元级B+轮融资。本轮融资获得了国泰海通证券旗下国泰君安创新投 资有限公司的独家投资，同时战略股东康基医疗继续追加投资，歌路资本担任本次交易的独家财务顾问。 此次募集资金将主要用于加速产品商业化进程，并推动新一代产品的研发与临床注册。 唯精医疗的核心团队源自哈尔滨工业大学机器人技术与系统全国重点实验室，是业内鲜有的、连续承担国家"十一五"至"十三五"系列863计划及重点研发计 划微创手术机器人项目的团队。 围绕外科手术中"看不清"与"做不到"的临床痛点，唯精医疗打造了极具竞争力的产品矩阵，在技术层面实现了多项重大突破： 手术体验革新：产品通过双目 4K显示与延迟低 ...

截至2025年12月26日收盘，金达莱（688057）报收于12.35元，较上周的11.95元上涨3.35%。本周，金 达莱12月22日盘中最高价报13.5元。12月24日盘中最低价报12.2元。金达莱当前最新总市值34.09亿元， 在环境治理板块市值排名71/106，在两市A股市值排名4295/5178。 公司公告汇总 江西金达莱环保股份有限公司拟使用自有资金3000万元向北京中科鸿泰医疗科技有限公司增资，获得其 10.00%的股权。标的公司专注于医疗机器人技术与系统的研发、生产及销售，是中科院自动化研究所 孵化的企业，具备较强科研实力，拥有多项自主知识产权，产品已进入国家药监局创新医疗器械特别审 查程序。本次交易为非同比例增资，不构成重大资产重组或关联交易。公司本次投资旨在优化产业结 构，培育新的利润增长点。投资完成后，公司合并报表范围不变。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本周关注点 公司公告汇总：金达莱拟使用自有资金3000万元向北京中科鸿泰医疗科技有限公司增资，获得其 10.00%的股权。 ...

12月26日，杭州康基唯精医疗机器人有限公司宣布已完成亿元级B+轮融资。本轮融资获得了国泰君安 创新投资有限公司的独家投资，同时战略股东康基医疗继续追加投资，歌路资本担任本次交易的独家财 务顾问。此次募集资金将主要用于加速产品商业化进程，并推动新一代产品、功能的研发与临床注册。 唯精医疗公司核心团队源自哈尔滨工业大学机器人技术与系统全国重点实验室，从2003年在哈工大实验 室开始基础研究，到如今产品进入全国顶尖医院临床应用，这二十年来，团队累计申请专利400余项。 （唯精医疗） 此外，唯精医疗在具身智能领域持续深耕，尤其在远程手术与人工智能术中导航等前沿方向，公司研发 团队紧密围绕临床实际需求与行业难点，开展了具有差异化的创新研发。例如，其术中导航系统能够对 关键解剖结构进行实时识别与提示，帮助外科医生精准规划手术路径，从而有效规避术中风险，显著提 升了手术的安全性及操作精度。 唯精医疗的核心产品四臂腹腔镜手术机器人（国械注准20253010806）已于2025年4月获得注册证，标志 着国产手术机器人正式进入规模化临床应用新阶段。临床数据显示无一例需要中转开展传统开腹手术， 这一数据无可辩驳地证明了系统在处理 ...

Core Viewpoint - Company Jindalai (688057) is diversifying into the medical sector by investing in two companies focused on stem cell research and medical robotics, following a decline in its performance since its IPO. The market reacted positively to these announcements, with a stock price increase of over 11% on December 22 [1][4]. Investment Details - Jindalai plans to invest CNY 280 million in Yunnan Jici Medical Technology Co., acquiring a 34% stake, and CNY 30 million in Zhongke Hongtai Medical Technology Co., acquiring a 10% stake [3][4]. - Jici Medical specializes in autologous cell technology and has conducted safety and efficacy validations for over 30 clinical indications [3]. - Zhongke Hongtai focuses on medical robotics and has completed clinical trials for its vascular intervention surgery robot [3][4]. Financial Performance - Jindalai has faced declining revenues and profits since its IPO, with revenues dropping from CNY 9.71 billion in 2020 to CNY 4.09 billion in 2024, and net profits decreasing from CNY 3.87 billion to CNY 1.37 billion in the same period [9]. - For the first three quarters of 2024, Jindalai reported revenues of approximately CNY 236 million, a 23.5% year-on-year decline, and net profits of CNY 75 million, down 30.14% [9]. Risks and Concerns - Both target companies present financial risks: Zhongke Hongtai has not yet achieved profitability, while Jici Medical has negative net assets, indicating it is in a state of insolvency [6][7]. - The investments are made at a premium, with Jici Medical's valuation at CNY 544 million, raising concerns about the potential for future returns [8]. - The medical technology sector is characterized by high barriers to entry and significant R&D costs, which may pose challenges for Jindalai, a company primarily focused on environmental services [10].

Core Viewpoint - Jindalai, a water environment management company, is diversifying into the healthcare sector by investing in two medical technology firms, despite facing financial uncertainties in these target companies [1][5]. Group 1: Investment Details - Jindalai plans to invest CNY 280 million in Yunnan Jici Medical Technology Co., acquiring a 34% stake, focusing on autologous cell technology [2]. - The company will also invest CNY 30 million in Zhongke Hongtai Medical Technology Co., obtaining a 10% stake, which specializes in medical robotics [2]. - Both investments are seen as a strategic move to optimize Jindalai's industry structure and enhance its risk resilience [3]. Group 2: Financial Performance of Target Companies - Zhongke Hongtai reported revenues of approximately CNY 132,100 and CNY 102,600 for the last year and the first three quarters of this year, respectively, with net losses of CNY 11.4 million and CNY 5.5 million [5]. - Jici Medical's revenues were CNY 8.69 million and CNY 11.23 million for the same periods, with net profits of CNY 2.23 million and CNY 1.15 million [5]. - As of the end of Q3 this year, Jici Medical had negative net assets of CNY 31.53 million, indicating a state of insolvency [5]. Group 3: Valuation and Risks - The investments are made at a premium, with Jici Medical's assessed value at CNY 544 million, primarily due to the value of its patents and ongoing projects [6]. - The success of Jici Medical's business and financial outlook heavily relies on the successful clinical development and commercialization of its drug candidates [6].

Core Viewpoint - Company Jindalai is making a significant shift into the health sector by investing over 310 million yuan in two companies, marking its transition from environmental protection to a dual focus on "environment + health" [2] Investment Details - Jindalai announced an investment of 280 million yuan to acquire a 34% stake in Jici Medical, focusing on cell therapy, and an additional 30 million yuan for a 10% stake in Zhongke Hongtai, which specializes in medical robotics [2][6] - The investment in Jici Medical positions Jindalai as the second-largest shareholder, just behind the controlling shareholder [3] Financial Performance of Target Companies - Jici Medical reported revenues of 11.23 million yuan and a net profit of 1.15 million yuan for the first three quarters of 2025, but its equity remains negative at -3.15 million yuan [4] - Zhongke Hongtai's revenue for the same period was only 102,600 yuan, with a net loss of 550,770 yuan, indicating ongoing financial challenges [6] Strategic Alignment with National Policies - Both investments align with national strategic emerging industries, with Jici Medical focusing on cell therapy and Zhongke Hongtai on the trend of intelligent medical devices [6] - The "14th Five-Year Plan" identifies biomanufacturing as a new economic growth point, with stem cell technology included as a key area [6] Challenges in Core Business - Jindalai's core environmental business is under pressure, with a revenue decline of 23.5% year-on-year for the first three quarters of 2025, leading to a search for new growth avenues [8] - The company is facing a "collection battle" with multiple lawsuits, indicating difficulties in cash flow management [9][12] Cash Flow and Investment Risks - Despite current cash flow stability, with over 2.2 billion yuan in liquid assets, future investments in the new sectors may strain resources, especially given the financial status of the target companies [14] - The high-risk nature of clinical trials in cell therapy and the complex registration processes for medical robots pose additional uncertainties for Jindalai's new ventures [14][15] Technical Synergy Concerns - There is limited technical synergy between Jindalai's core wastewater treatment technology and the new health sector investments, which may hinder the company's ability to leverage its existing expertise [15]

Core Viewpoint - Company Jindalai (688057) is diversifying into the medical sector by investing in two companies focused on stem cell research and medical robotics, despite facing declining performance in its core water treatment business since its IPO [1][10]. Investment Details - Jindalai plans to invest CNY 280 million in Yunnan Jici Medical Technology Co., acquiring a 34% stake, which focuses on the development and application of autologous cell technology [4]. - The company also intends to invest CNY 30 million in Zhongke Hongtai Medical Technology Co., obtaining a 10% stake, which specializes in medical robotics [4]. - Both investments are seen as cross-industry moves for Jindalai, which has traditionally focused on water environment management [5]. Financial Performance - Jindalai has experienced a decline in revenue and net profit for four consecutive years since its IPO, with revenues dropping from CNY 9.71 billion in 2020 to CNY 4.09 billion in 2024 [11]. - In the first three quarters of 2024, Jindalai reported revenues of approximately CNY 236 million, a year-on-year decrease of 23.5%, and a net profit of CNY 75 million, down 30.14% [11]. Risks and Concerns - Both target companies present financial risks: Zhongke Hongtai has not yet achieved profitability, while Jici Medical has negative net assets, indicating a state of insolvency [7][8]. - The investments are made at a premium, with Jici Medical's assessed value at CNY 5.44 billion, raising concerns about the potential for future returns [9]. - The medical technology sector is characterized by high barriers to entry and significant R&D costs, which may pose challenges for Jindalai, a company lacking experience in this field [12].

Core Viewpoint - Jiangxi Jindalai Environmental Protection Co., Ltd. is making significant moves towards diversification by investing in the healthcare sector, specifically in stem cell technology and medical robotics, to optimize its industrial structure and cultivate new profit growth points [2][3][21]. Investment in Healthcare - On December 19, Jindalai announced an investment of 280 million yuan in Yunnan Jici Medical Technology Co., Ltd., acquiring a 34% stake, making it the second-largest shareholder [2][21]. - On December 21, the company announced an additional investment of 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake [3][21]. - Both investments target the "big health industry," with Jici Medical focusing on proprietary stem cell technology and Zhongke Hongtai excelling in medical artificial intelligence [3][21]. Rationale for Investment - Jindalai aims to respond to national calls for investment in biomanufacturing and healthcare sectors, enhancing its risk resistance and creating new profit avenues [3][21]. - The company believes that the aging population and the maturation of the industry in China present ample investment opportunities in the big health sector [3][21]. Financial Overview of Jici Medical - As of September 30, Jici Medical reported total assets of 10.01 million yuan, with revenues and net profits of 11.23 million yuan and 1.15 million yuan, respectively, for the first nine months of 2025 [6][26]. - Despite not being particularly strong financially, Jici Medical's ability to generate initial self-sustaining revenue is notable in the capital-intensive biomanufacturing sector [6][26]. Financial Overview of Zhongke Hongtai - Zhongke Hongtai reported total assets of 61.58 million yuan and a net loss of 5.51 million yuan for the first nine months of 2025 [10][31]. - The company is recognized for its innovative medical robotics and has completed 16 clinical trials for its products, which are currently in the regulatory approval process [10][31]. Jindalai's Current Position - Jindalai has a strong financial position, with a debt ratio of only 10.2% and cash reserves exceeding 1.898 billion yuan, allowing it to fund these investments entirely with its own capital [12][33]. - However, the company has experienced a decline in its main business, with a 23.5% drop in total revenue and a 30.14% decrease in net profit for the first nine months of 2025 [13][33]. Strategic Shift - The investments in Jici Medical and Zhongke Hongtai mark Jindalai's formal entry into the biomanufacturing and big health sectors, aligning with national policies that support these industries as emerging growth areas [16][36]. - The company is part of a broader trend among environmental firms diversifying into non-environmental sectors, with nearly half of the listed environmental companies exploring such opportunities [17][38].

Core Viewpoint - Jindalai (688057) has announced an investment of 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd. to acquire a 10% stake, aiming to optimize its industrial structure and cultivate new profit growth points [1] Group 1: Stock Performance - As of December 22, 2025, Jindalai's stock closed at 12.4 yuan, up 3.77% from the previous trading day, with a total market capitalization of 3.422 billion yuan [1] - The stock opened at 13.0 yuan, reached a high of 13.5 yuan, and a low of 12.38 yuan, with a trading volume of 92.2442 million yuan and a turnover rate of 2.58% [1] Group 2: Investment Details - Jindalai plans to use its own funds of 30 million yuan for the investment, which is classified as a non-proportional capital increase and does not constitute a major asset restructuring or related party transaction [1] - The target company, Beijing Zhongke Hongtai, focuses on the research, production, and sales of medical robot technology and systems, and is incubated by the Chinese Academy of Sciences' Institute of Automation, possessing strong research capabilities and multiple independent intellectual property rights [1] - The products of the target company have entered the special review process for innovative medical devices by the National Medical Products Administration [1]

Group 1 - Guanshang Technology plans to issue shares for asset acquisition and will suspend trading from December 22, 2025, with a disclosure of the transaction plan expected within 10 trading days [1][15][16] - *ST Dongyi's restructuring plan has been approved by the Beijing First Intermediate People's Court, entering the execution phase, which may improve the company's financial structure and affect its 2025 financial data [2][17] - Victory Energy's stock has hit the limit up for six consecutive trading days, with a total increase of 77.22%, indicating a significant deviation from market trends and a potential risk of rapid decline [3][18] Group 2 - Shangfeng Cement's investee, Yuexin Semiconductor, has received approval for its IPO application on the ChiNext board, with the company holding approximately 1.4957% of the equity before the public offering [4][19] - Jindalai plans to invest 30 million yuan in Zhongke Hongtai Medical Technology Co., acquiring a 10% stake in the company, which specializes in medical robotics [5][20] - Lianchuang Electronics is planning a change of control, leading to a continued suspension of its stock from December 22, 2025, for no more than three trading days [6][21] Group 3 - Health元's subsidiary has received approval for clinical trials of NS-041 tablets for treating depression, making it the only drug in China approved for both epilepsy and depression clinical studies [7][22] - Xihua Technology will be listed on the Shanghai Stock Exchange main board on December 23, 2025, with an initial public offering of 100 million shares [8][23] - *ST Mingjia has completed the capital reserve transfer to increase its share capital, resulting in an increase from 696 million shares to 1.426 billion shares, with stock resuming trading on December 22, 2025 [9][24][25]